These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12210816)

  • 1. Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy.
    Conesa V; Mompel A; Lopez F; Marín F; Ruiz J; Navarro F; Gomez A
    Am J Hematol; 2002 Aug; 70(4):329-30. PubMed ID: 12210816
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII.
    Koyama T; Nagao T; Tsunozaki H; Arai M; Miura O
    Pathophysiol Haemost Thromb; 2006; 35(5):405-7. PubMed ID: 17230044
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
    Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
    Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant FVIIa in the treatment of bleeding in acquired hemophilia.
    Guerin V; Chossat I; Dutronc H; Dubreuil M; Valentin F
    Am J Hematol; 2002 Aug; 70(4):333. PubMed ID: 12210820
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost minimization model for treatment of minor bleeding episodes in inhibitor patients -- methodological issues.
    Seremetis S; Joshi AV; Asmussen M
    Haemophilia; 2006 Jan; 12(1):108-9. PubMed ID: 16409187
    [No Abstract]   [Full Text] [Related]  

  • 6. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
    Negrier C
    J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis.
    Borrás-Blasco J; Conesa-García V; Navarro-Ruiz A; Palacios-Ortega F; Gómez A
    Pancreas; 2005 Oct; 31(3):292-4. PubMed ID: 16163065
    [No Abstract]   [Full Text] [Related]  

  • 8. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
    Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
    Baudo F; de Cataldo F; Gaidano G;
    Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired hemophilia as a cause of primary postpartum hemorrhage.
    Borna S; Hantoushzadeh S
    Arch Iran Med; 2007 Jan; 10(1):107-10. PubMed ID: 17198466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ischemic colitis following the treatment of acute hemorrhage in a patient with acquired hemophilia A].
    Suzuki T; Arai A; Koyama T; Oshikawa G; Yamamoto M; Mizuchi D; Kurosu T; Tohda S; Murakami N; Miki T; Miura O
    Rinsho Ketsueki; 2006 Apr; 47(4):310-4. PubMed ID: 16715966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NovoSeven for non-hemophilia hemostasis.
    Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    Siegmund B; Richter H; Pollmann H
    Haemophilia; 2005 Nov; 11(6):638-41. PubMed ID: 16236116
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
    Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
    Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of recombinant factor VIIa: continue or not?
    Ewenstein BM
    Thromb Haemost; 2001 Oct; 86(4):942-4. PubMed ID: 11686349
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?
    Rivard GE; Lillicrap D; Poon MC; Demers C; Lépine M; St-Louis J; Warner M
    Haemophilia; 2005 Jul; 11(4):335-9. PubMed ID: 16011584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy.
    Key NS; Christie B; Henderson N; Nelsestuen GL
    Thromb Haemost; 2002 Jul; 88(1):60-5. PubMed ID: 12152680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII.
    Guillet B; Pinganaud C; Proulle V; Dreyfus M; Lambert T
    Thromb Haemost; 2002 Oct; 88(4):698-9. PubMed ID: 12362252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.